Available Trials

Breast

NEW: USOR 18042 A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study Of Talazoparib For Neoadjuvant Treatment Of Germline BRCA 1/2 Mutation Patients With Early Triple-Negative Breast Cancer. (C3441020)
Available at: Arlington Heights, Niles
USOR 16195 A Phase 2, Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated, Unresectable, Locally Advanced or Metastatic HER2+ Breast Carcinoma. USOR 16195 (STAR ONT 380 206)
Available at: Arlington Heights, Niles
ECOG-ACRIN S1207 A Phase III, Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer.
Available at: Arlington Heights, Niles
ECOG-ACRIN 1131 A Randomized, Phase III Post-Operative Trial of Platinum Base Chemotherapy vs Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Therapy.
Available at: Arlington Heights, Niles
USOR 16128 POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study. (A5481081)
Available at: Arlington Heights, Niles

Colorectal

Gastric

USOR 16164 Randomized, Multi-Center, Open-Label, Phase 3, Study of Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine vs. Oxaliplatin Plus Fluoropyrimidine in Subjects with Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. (BMS CA 209-649)
Available at: Arlington Heights, Niles

Gastric/Gastroesophageal

USOR 16164 Randomized, Multi-Center, Open-Label, Phase 3, Study of Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine vs. Oxaliplatin Plus Fluoropyrimidine in Subjects with Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. (BMS CA 209-649)
Available at: Arlington Heights, Niles

Hematology

USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)
Available at: Arlington Heights, Niles

Leukemia

Lung - Non-Small Cell Lung

Lung - Small Cell Lung

NEWLY OPENED USOR 18031: A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-Argl-PEG) in Combination with Pembrolizumab in the Treatment of Patients with Extensive Disease (ED) Small Cell Lung Cancer (SCLC) (CAEB1102-101B)
Available at: Arlington Heights, Niles

Lymphoma

Multiple Myeloma

Pancreas

PNH

USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)
Available at: Arlington Heights, Niles

Solid Tumor

USOR 16041 AN OPEN-LABEL PHASE 2 MULTI-COHORT TRIAL OF NIVOLUMAB IN ADVANCED OR METASTATIC MALIGNANCIES. HOLDING. CONTACT RESEARCH FOR OPEN COHORTS. USOR 16041 (CA 209-627)
Available at: Arlington Heights, Niles

Available Trials

Breast

NEW: USOR 18042 A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study Of Talazoparib For Neoadjuvant Treatment Of Germline BRCA 1/2 Mutation Patients With Early Triple-Negative Breast Cancer. (C3441020)

USOR 16195 A Phase 2, Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated, Unresectable, Locally Advanced or Metastatic HER2+ Breast Carcinoma. USOR 16195 (STAR ONT 380 206)

ECOG-ACRIN S1207 A Phase III, Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer.

ECOG-ACRIN 1131 A Randomized, Phase III Post-Operative Trial of Platinum Base Chemotherapy vs Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Therapy.

USOR 16128 POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study. (A5481081)

Colorectal

USOR 17186: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy versus Standard of Care Therapy For First Line Treatment of Metastatic Colorectal Cancer. (CA209-9X8) (USOR 17186)

USOR 16130 A Phase III Study of BBI-608 in Combination with 5-Fluorouracil, Leucovorin, Irinotecan (Folfiri) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC). (CanStem303C)

Gastric

USOR 16164 Randomized, Multi-Center, Open-Label, Phase 3, Study of Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine vs. Oxaliplatin Plus Fluoropyrimidine in Subjects with Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. (BMS CA 209-649)

Gastric/Gastroesophageal

USOR 16164 Randomized, Multi-Center, Open-Label, Phase 3, Study of Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine vs. Oxaliplatin Plus Fluoropyrimidine in Subjects with Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. (BMS CA 209-649)

Hematology

Leukemia

AGIOS AG120-C-009 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age and Older, with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation.

ECOG-ACRIN 1910 A Phase III, Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B Lineage Acute Lymphoblastic Leukemia in Adults.

Lung - Non-Small Cell Lung

USOR 17063/TSR-022: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors: NSCLC. USOR 17063 (4020-01-001)

ECOG-ACRIN-4512 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib vs Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.

USOR 16156 A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer. (CA209-817)

USOR 16161 A Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab Versus Platinum-Doublet Chemotherapy in Early Stage NSCLC. (CA209-816)

Lung - Small Cell Lung

NEWLY OPENED USOR 18031: A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-Argl-PEG) in Combination with Pembrolizumab in the Treatment of Patients with Extensive Disease (ED) Small Cell Lung Cancer (SCLC) (CAEB1102-101B)

Lymphoma

USOR 17093/CITADEL-205 A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Ka Inhibitor, In Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) - INCB050465-205.

USOR 16065 Relapsed/Refractory - A Phase 2b, Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma. (UTX-TGR-205)

USOR 11282 1st Line - A Phase 2, Single-Arm, Open-Label Study of Single-Agent Brentuximab Vedotin for Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above.(SGN35-015)

USOR 16100 Hodgkins Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices. (CA20965)

Multiple Myeloma

USOR 16035 Registry - A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - The Insight MM Study. (NSMM-5001)

Pancreas

NEWLY OPENED USOR 17160 / PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Testing Fields (TTFields, 150kHz) concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma (EF-27)

USOR 16187: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301) USOR 16187

PNH

Solid Tumor

USOR 16041 AN OPEN-LABEL PHASE 2 MULTI-COHORT TRIAL OF NIVOLUMAB IN ADVANCED OR METASTATIC MALIGNANCIES. HOLDING. CONTACT RESEARCH FOR OPEN COHORTS. USOR 16041 (CA 209-627)

Treatments & Services